FinDogFinDog
Wednesday, September 16, 2026Closing data · 4:00 PM ET
English
Log in

CRL

Charles River LaboratoriesNYSE · Life Sciences Tools & Services · Health Care
Previous close
273.41
Change
+0.53 / +0.19%
FinDog View
Neutral
52-Week Range
144.26 – 303.31
P/E (TTM)
—
Forward P/E
24.2
Based on consensus earnings for the next 12 months
Market Cap
$13.1B
1M
−4.62%
S&P 500 −2.41% over same period
Volume / Avg Volume
1.0M / 842K
1.20× average

Price History

Closing price · USD1M6M1Y5Y
0100200300400500FY26 Q2 EarningsFY26 Q1 EarningsFY25 Q4 EarningsFY25 Q3 EarningsFY25 Q2 EarningsFY25 Q1 Earnings2021-092022-122024-032025-062026-09

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis
FY2026 Q2
Quarter ended 2026-06
2026-08-05$1.0B3.02 / 2.76+1.84%Pending
FY2026 Q1
Quarter ended 2026-03
2026-05-07$996M2.06 / 1.96−2.23%Pending
FY2025 Q4
Quarter ended 2025-12
2026-01-13—— / —−1.19%Pending
FY2025 Q3
Quarter ended 2025-09
2025-11-05—— / —+1.90%Pending
FY2025 Q2
Quarter ended 2025-06
2025-08-06—— / —−0.37%Pending
FY2025 Q1
Quarter ended 2025-03
2025-05-07—— / —+3.21%Pending

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
A 5-year P/E range needs a longer earnings record; not yet comparable
Last 4 quarters: $324M in buybacks + $0 in dividends, 2.48% of market cap combined
P/E (TTM)
—
P/B
4.6
P/S
3.3
PEG
—
Earnings Reaction
Over the last 6 reports, the stock moved ±1.8% on average on the first trading day after, rising 3 times
Most recent +1.84%
Volatility & Correlation
1-year beta 1.28 · Correlation with S&P 500 0.36Tracks the market
Annualized volatility 45% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 10 · $42.6MNet selling $42.6M
  • 08-25FOSTER JAMES CDirectorSell$10.1M33,561 shares · Avg price 300.00
  • 08-19Parisotto Shannon MCEVP, Disc & Safety AssessmentSell$0.60M2,039 shares · Avg price 294.12
  • 08-18Andrews Nancy CDirectorSell$0.16M573 shares · Avg price 285.24
  • 08-11Parisotto Shannon MCEVP, Disc & Safety AssessmentSell$1.0M3,714 shares · Avg price 279.66
  • 08-11Girshick BirgitChief Executive OfficerSell$1.8M6,500 shares · Avg price 279.90
  • 08-10FOSTER JAMES CDirectorSell$7.9M28,733 shares · Avg price 275.00
  • 08-06Creamer Victoria LEVP & Chief People OfficerSell$1.1M4,179 shares · Avg price 259.16
  • 08-06Knell Michael GunnarSVP, Finance and CAOSell$1.7M6,645 shares · 9 trades · Avg price 260.38
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q21.00−2.7%—0.12-0.000.18-0.03
FY2026 Q11.00+1.2%—0.12-0.010.04-0.30
FY2025 Q40.99−0.8%—-0.28-0.280.15-5.57
FY2025 Q31.00−0.5%—0.130.050.211.10
FY2025 Q21.03+0.6%—0.100.050.201.06
FY2025 Q10.98−2.7%—0.070.030.170.50
FY2024 Q41.00−1.1%—-0.17-0.210.16-4.17
FY2024 Q31.01−4.7%34.6%0.120.070.251.33
FY2024 Q21.03−0.3%34.5%0.150.090.191.74
FY2024 Q11.01—34.1%0.130.070.131.30
FY2023 Q41.01−7.9%—0.130.190.223.63
FY2023 Q31.06+7.2%37.6%0.160.100.151.89

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView
CRLCharles River Laboratories$13.1B—−2.7%—−4.62%Neutral
LLYLilly (Eli)$1.07T39.9+47.7%85.8%−3.83%BullishCompare
JNJJohnson & Johnson$644B30.6+6.6%68.2%+1.87%BullishCompare
ABBVAbbVie$464B73.7+10.2%74.7%+4.87%NeutralCompare
MRKMerck & Co.$358B112.2+5.1%73.5%+6.57%NeutralCompare
UNHUnitedHealth Group$337B23.9+0.4%88.1%−5.15%NeutralCompare
TMOThermo Fisher Scientific$240B34.4+10.5%—+10.75%BullishCompare
AMGNAmgen$203B23.3+9.5%72.0%−10.26%NeutralCompare
GILDGilead Sciences$183B—+10.2%79.8%+6.31%NeutralCompare